BeiGene announced that the US Food and Drug Administration has approved Baizean®'s marketing license application for additional indications, that is, in combination with Baihean® and chemotherapy for first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma.

Zhitongcaijing · 3d ago
BeiGene announced that the US Food and Drug Administration has approved Baizean®'s marketing license application for additional indications, that is, in combination with Baihean® and chemotherapy for first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma.